Manidipina Pharmacare (Manidipine Dihydrochloride)

Manidipine, the active ingredient in Manidipina Pharmacare, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure in adult patients requiring antihypertensive therapy, offering vascular smooth‑muscle relaxation and peripheral resistance reduction.

GNH USA supplies Manidipina Pharmacare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global cardiovascular care programs, and ensuring compliance with EU standards.

Manidipine is a calcium channel blocker indicated for the treatment of hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: reduces both systolic and diastolic blood pressure. - Isolated systolic hypertension: helps achieve target systolic pressure. - Diastolic hypertension: contributes to lowering diastolic pressure.

Manidipine may be associated with several adverse reactions, ranging from frequent, mild events to rare but serious conditions.

Common Side Effects: - Headache: mild to moderate headache. - Flushing: transient facial flushing. - Peripheral edema: swelling of ankles or feet. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Manidipine, clinicians should consider several precautionary measures to ensure safe use.

- Monitor blood pressure: check regularly after initiation and dose adjustments. - Assess hepatic function: use with caution in patients with liver impairment. - Review concomitant antihypertensives: avoid excessive hypotension when combined with other agents. - Use cautiously in the elderly: increased sensitivity to vasodilatory effects. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Manidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase manidipine plasma concentrations. - Grapefruit juice: can markedly raise drug levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Beta‑blockers: combined use can increase risk of bradycardia and hypotension. - ACE inhibitors or ARBs: concurrent therapy may potentiate blood pressure lowering.